BC Week In Review | Sep 29, 2014
Clinical News

MNK-155: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 403 patients with moderate to severe acute pain following a unilateral first metatarsal bunionectomy showed that a loading dose of 3 tablets of oral MNK-155...
BC Week In Review | Jun 9, 2014
Clinical News

MNK-155 regulatory update

Mallinckrodt said FDA accepted for review an NDA for MNK-155 - an extended-release oral formulation of hydrocodone and acetaminophen using Depomed's AcuForm technology - to manage moderate to moderately severe acute pain where the use of an...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BC Week In Review | Dec 16, 2013
Clinical News

MNK-155: Phase III data

A double-blind, U.S. Phase III trial in about 400 patients with moderate to severe acute pain following a unilateral first metatarsal bunionectomy showed that a loading dose of 3 tablets of oral MNK-155 followed by...
BC Extra | Dec 13, 2013
Clinical News

Mallinckrodt product meets in Phase III pain trial

Mallinckrodt plc (NYSE:MNK) said MNK-155 met the primary endpoint vs. placebo in a Phase III trial to manage moderate to severe acute pain where the use of an opioid analgesic is appropriate. In the double-blind...
Items per page:
1 - 5 of 5